Merck & Co. last week announced a series of price cuts on some of its drugs, and among them was a 60 percent reduction on the price of Zepatier, a hepatitis C treatment.
The drug, however, is reportedly far from the drugmaker’s best performing suite.
Zepatier, according to a MarketWatch report, has seen a consistent decline in sales after having reached its peak at $517 million. In the last quarter, the drug was responsible for only $113 million, and Wall Street analysts expect sales to skid to $30 million by next summer.
According to the report, the drug has also been consistently outperformed by rival treatments.